Funding for this research was provided by:
French Ministry of Health (PHRC-15-0011)
Received: 2 April 2019
Accepted: 30 December 2019
First Online: 31 January 2020
Ethics approval and consent to participate
: TRAAP2 trial was approved-by the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) (national agency for drug safety), August 18, 2017.-by the Comité de Protection des Personnes (CPP North West IV) (Committee for protection of persons involved in biomedical research), September 12, 2017.-by the Commission Nationale de l’Information et des Libertés (CNIL) (French data protection authority), October 19, 2017.Informed written consent will be obtained from all participants.
: Not applicable.
: Dr. Sentilhes reports receiving lecture and consulting fees from Ferring, and lecture fees from Bayer, GSK and SIGVARIS. Dr. Daniel reports receiving lecture and consulting fees from LFB. No other potential conflict of interest relevant to this article was reported.